CAJ | 학술논문

目的：探讨沙美特罗/丙酸氟替卡松联合盐酸氨溴索对慢性阻塞性肺疾病(COPD)患者肺功能和血气指标的影响。方法选取2011年1月~2014年6月在本院就诊的确诊为COPD的患者200例，根据治疗方法不同分为观察组和对照组，对照组给予沙美特罗/丙酸氟替卡松(沙美特罗50μg/丙酸氟替卡松250μg)每次1吸，2次/d。观察组在对照组治疗的基础上给予盐酸氨溴索30 mg，口服，2次/d。观察两组肺功能和血气指标的变化。结果治疗前两组患者的FEV1，FVC、FEV1/FVC，FEV1%比较，差异无统计学意义(P>0.05)；治疗后3个月观察组的FEV1、FVC、FEV1/FVC、FEV1%高于对照组，差异有统计学意义(P<0.05)。治疗前两组患者的PaO2、PaCO2比较，差异无统计学意义(P>0.05)；治疗后3个月观察组的PaO2高于对照组，PaCO2低于对照组，差异有统计学意义(P<0.05)。治疗后3个月，观察组急性发作0次者90例(90%)，对照组急性发作0次者73例(73%)，两组急性发作0次者比率差异有统计学意义(P<0.05)。结论沙美特罗/丙酸氟替卡松联合盐酸氨溴索治疗COPD效果明显，可有效改善患者肺功能及血气指标，提高患者的生活质量。
목적：탐토사미특라/병산불체잡송연합염산안추색대만성조새성폐질병(COPD)환자폐공능화혈기지표적영향。방법선취2011년1월~2014년6월재본원취진적학진위COPD적환자200례，근거치료방법불동분위관찰조화대조조，대조조급여사미특라/병산불체잡송(사미특라50μg/병산불체잡송250μg)매차1흡，2차/d。관찰조재대조조치료적기출상급여염산안추색30 mg，구복，2차/d。관찰량조폐공능화혈기지표적변화。결과치료전량조환자적FEV1，FVC、FEV1/FVC，FEV1%비교，차이무통계학의의(P>0.05)；치료후3개월관찰조적FEV1、FVC、FEV1/FVC、FEV1%고우대조조，차이유통계학의의(P<0.05)。치료전량조환자적PaO2、PaCO2비교，차이무통계학의의(P>0.05)；치료후3개월관찰조적PaO2고우대조조，PaCO2저우대조조，차이유통계학의의(P<0.05)。치료후3개월，관찰조급성발작0차자90례(90%)，대조조급성발작0차자73례(73%)，량조급성발작0차자비솔차이유통계학의의(P<0.05)。결론사미특라/병산불체잡송연합염산안추색치료COPD효과명현，가유효개선환자폐공능급혈기지표，제고환자적생활질량。
Objective To investigate the effect of salmeterol/fluticasone propionate combined with ambroxol on pul-monary function and blood gas in patients with chronic obstructive pulmonary disease (COPD). Methods 200 cases of patients with COPD in our hospital from January 2011 to June 2014 were selected,according to the different treatment methods,they were divided into observation group and control group,the control group were treated with salmeterol/fluti-casone propionate (salmeterol 50 μg/ fluticasone propionate 250 μg) every time 1 suction,2 times a day;ambroxol was added to the observation group on the basis of control group,30 mg orally 2 times a day.The pulmonary function and blood gas index of the two groups was observed. Results Before treatment,the FEV1,FVC,FEV1/FVC,FEV1% of two groups had no significant (P>0.05);after 3 months treatment,the FEV1,FVC,FEV1/FVC,FEV1% of observation group was higher than that of control group,the difference was significant (P<0.05).Before treatment,the PaO2 and PaCO2 of two groups had no significant (P>0.05);after 3 months treatment,PaO2 of the observation group was higher than that of the con-trol group,PaCO2 was lower than that of the control group (P<0.05).After 3 months treatment,the acute attack of 0 time rate of observation group was 90%,the control group was 73%,there was significant difference (P<0.05). Conclusion The clini-cal curative efficacy of salmeterol/fluticasone propionate combined with ambroxol in the treatment of COPD is apparent, it can effectively improve the patients’pulmonary function and blood gas index,and improve the life quality of patients.